Why Allakos Stock Is Crashing Today
Shares of Allakos (NASDAQ: ALLK) are crashing 88% lower as of 10:17 a.m ET on Wednesday. The huge decline came after the company announced results from its phase 3 Enigma 2 and its phase 2/3 Kryptos clinical studies evaluating lirentelimab.
Allakos reported that both clinical studies met their histologic co-primary endpoints. However, neither study achieved statistically significant improvement on patient-reported symptomatic co-primary endpoints.
Image source: Getty Images.
Source Fool.com